Nasus Pharma (NSRX) Reiterated at Market Outperform by Citizens

June 11, 2026 5:15 AM

Citizens analyst Jason Butler reiterated a Market Outperform rating and $18.00 price target on Nasus Pharma Ltd (NYSE: NSRX).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found